Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tezepelumab - Amgen/AstraZeneca

Drug Profile

Tezepelumab - Amgen/AstraZeneca

Alternative Names: AMG 157; MEDI-9929

Latest Information Update: 05 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bispebjerg Hospital; Lund University; MedImmune; University of Copenhagen; University of Newcastle, Australia
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma
  • Phase II Atopic dermatitis

Most Recent Events

  • 28 Oct 2018 No recent reports of development identified for phase-I development in Asthma(In adolescents) in Poland (SC, Injection)
  • 23 Oct 2018 Phase-II clinical trials in Asthma (Treatment-experienced, in adults, In the elderly) in Denmark (SC) (NCT03688074; EudraCT2018-002069-21)
  • 15 Oct 2018 AstraZeneca plans the DESTINATION phase III trial for Asthma in USA and Russia (NCT03706079)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top